Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $58.0 million.

  • Rxo's Change in Account Payables rose 42222.22% to $58.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$16.0 million, marking a year-over-year increase of 7538.46%. This contributed to the annual value of -$16.0 million for FY2025, which is 7538.46% up from last year.
  • According to the latest figures from Q4 2025, Rxo's Change in Account Payables is $58.0 million, which was up 42222.22% from $19.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Change in Account Payables registered a high of $216.0 million during Q1 2022, and its lowest value of -$121.0 million during Q2 2022.
  • In the last 5 years, Rxo's Change in Account Payables had a median value of -$20.0 million in 2024 and averaged -$4.8 million.
  • Within the past 5 years, the most significant YoY rise in Rxo's Change in Account Payables was 42222.22% (2025), while the steepest drop was 36428.57% (2025).
  • Over the past 5 years, Rxo's Change in Account Payables (Quarter) stood at $99.0 million in 2021, then crashed by 139.39% to -$39.0 million in 2022, then increased by 23.08% to -$30.0 million in 2023, then surged by 40.0% to -$18.0 million in 2024, then skyrocketed by 422.22% to $58.0 million in 2025.
  • Its Change in Account Payables stands at $58.0 million for Q4 2025, versus $19.0 million for Q3 2025 and -$37.0 million for Q2 2025.